Works matching DE "ANTIPRURITICS"

Results: 95
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11

    Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation.

    Published in:
    Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-88118-6
    By:
    • Shokirova, Hurramhon;
    • Inomata, Takenori;
    • Saitoh, Tsuyoshi;
    • Zhu, Jun;
    • Fujio, Kenta;
    • Okumura, Yuichi;
    • Yanagawa, Ai;
    • Fujimoto, Keiichi;
    • Sung, Jaemyoung;
    • Eguchi, Atsuko;
    • Miura, Maria;
    • Nagino, Ken;
    • Hirosawa, Kunihiko;
    • Kuwahara, Mizu;
    • Akasaki, Yasutsugu;
    • Nagase, Hiroshi;
    • Murakami, Akira
    Publication type:
    Article
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24

    Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.

    Published in:
    American Journal of Clinical Dermatology, 2024, v. 25, n. 4, p. 669, doi. 10.1007/s40257-024-00855-2
    By:
    • Eichenfield, Lawrence F.;
    • Simpson, Eric L.;
    • Papp, Kim;
    • Szepietowski, Jacek C.;
    • Blauvelt, Andrew;
    • Kircik, Leon;
    • Silverberg, Jonathan I.;
    • Siegfried, Elaine C.;
    • Kuligowski, Michael E.;
    • Venturanza, May E.;
    • Kallender, Howard;
    • Ren, Haobo;
    • Paller, Amy S.
    Publication type:
    Article
    25
    26
    27
    28
    29
    30
    31
    32

    Pruritis part 1: Atopic eczema.

    Published in:
    Practice Nursing, 2009, v. 20, n. 11, p. 561, doi. 10.12968/pnur.2009.20.11.45049
    By:
    • Watkins, Jean
    Publication type:
    Article
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49

    What's this?

    Published in:
    InnovAiT, 2025, v. 18, n. 5, p. 290, doi. 10.1177/17557380241298152
    By:
    • Henderson, Lisa
    Publication type:
    Article
    50